Sonoma Pharmaceuticals, Inc. (SNOA) income statement
SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3082% below fair value
$0.83−0.01 (-0.76%)
Close on Nov 18, 2026Market cap $3.96MP/E –Yield –
Sonoma Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 38.9%
- Operating margin
- -6.4%
- Net margin
- -10.3%
- Return on equity, FY2026
- -84.6%
Financial strength
- Current ratio
- 2.99
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 98.0%
Valuation
- P/E ratio
- –
- Price to sales
- 0.18
- Price to book
- 0.60
- Dividend yield
- –
See a number that looks wrong?